For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Neogenomics Inc (NASDAQ: NEO) closed at $9.77 in the last session, up 0.83% from day before closing price of $9.69. In other words, the price has increased by $0.83 from its previous closing price. On the day, 2.61 million shares were traded. NEO stock price reached its highest trading level at $9.95 during the session, while it also had its lowest trading level at $9.42.
Ratios:
We take a closer look at NEO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.91. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 16 ’25 when ALICIA OLIVO bought 4,918 shares for $9.97 per share.
Sherman Jeffrey Scott bought 20,000 shares of NEO for $112,322 on Aug 06 ’25. The Chief Financial Officer now owns 188,332 shares after completing the transaction at $5.62 per share. On Aug 06 ’25, another insider, Zook Anthony P., who serves as the Chief Executive Officer of the company, bought 17,900 shares for $5.58 each. As a result, the insider paid 99,954 and bolstered with 38,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1264118912 and an Enterprise Value of 1510309760. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.78 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 2.13 whereas that against EBITDA is -104.016.
Stock Price History:
The Beta on a monthly basis for NEO is 1.66, which has changed by -0.30905235 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is 12.06%, while the 200-Day Moving Average is calculated to be 9.94%.
Shares Statistics:
According to the various share statistics, NEO traded on average about 3.46M shares per day over the past 3-months and 4473910 shares per day over the past 10 days. A total of 128.89M shares are outstanding, with a floating share count of 125.27M. Insiders hold about 3.19% of the company’s shares, while institutions hold 95.60% stake in the company. Shares short for NEO as of 1760486400 were 6508598 with a Short Ratio of 1.88, compared to 1757894400 on 5918913. Therefore, it implies a Short% of Shares Outstanding of 6508598 and a Short% of Float of 6.950000000000001.
Earnings Estimates
Neogenomics Inc (NEO) is presently subject to a detailed evaluation by 9.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.01, with high estimates of $0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.17 and $0.07 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.19, with 10.0 analysts recommending between $0.32 and $0.08.
Revenue Estimates
According to 13 analysts, . The current quarter’s revenue is expected to be $188.43M. It ranges from a high estimate of $190.21M to a low estimate of $186.6M. As of . The current estimate, Neogenomics Inc’s year-ago sales were $172MFor the next quarter, 13 analysts are estimating revenue of $188.2M. There is a high estimate of $194.32M for the next quarter, whereas the lowest estimate is $183M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $725.99M, while the lowest revenue estimate was $720.5M, resulting in an average revenue estimate of $724.49M. In the same quarter a year ago, actual revenue was $660.57MBased on 13 analysts’ estimates, the company’s revenue will be $795.62M in the next fiscal year. The high estimate is $805.3M and the low estimate is $784.8M.
